Whoopi Goldberg had some trouble pronouncing WNBA star Diana Taurasi's name on Wednesday morning so, when the athlete herself ...

TD Cowen raised the firm’s price target on Hims & Hers to $44 from $28 and keeps a Buy rating on the shares. The firm continues to believe ...

One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

Hims & Hers will stop selling generic semaglutide after the FDA said the shortage of GLP-1 medications is resolved.

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...